Accommodating IOL leads revenue surge

Aliso Viejo, CA-First-quarter 2007 revenues for eyeonics inc., the developer of the crystalens accommodating IOL, have increased 36% over the same period last year, the company said.

For the first quarter ended March 31, revenues totaled $5.5 million.

During this period, the sale of implants grew more than 45% year over year, the company reported. The crystalens, the first and only FDA-approved accommodating IOL, has been implanted in more than 70,000 patients worldwide.